In addition, both anti–CTLA-4/TGF-βRII and anti–PD-L1/TGF-βRII traps were more effective in inhibiting tumor progression compared with CTLA-4 or PD-L1 monotherapy in melanoma and breast cancer mouse models, which was associated with an elevation in tumor-reactive IFN-γ-expressing CD8+ cells and a reduction in Treg cells (60). The gene discussed is CTLA4; the disease is breast cancer.